CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.64 USD | 0.00% |
|
+0.61% | -44.03% |
| Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
| Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 118.2 | 68.13 | - | - |
| Enterprise Value (EV) 1 | 118.2 | 68.13 | 68.13 | 68.13 |
| P/E ratio | -1.13 x | -1.27 x | -1.23 x | -1.38 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 7.93 x | 4.02 x | 4.93 x | 3.01 x |
| EV / Revenue | 7.93 x | 4.02 x | 4.93 x | 3.01 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -1.44 x | -1.95 x | -1.25 x | -1.72 x |
| FCF Yield | -69.6% | -51.4% | -80% | -58% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 40,357 | 41,543 | - | - |
| Reference price 2 | 2.930 | 1.640 | 1.640 | 1.640 |
| Announcement Date | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 14.92 | 16.93 | 13.83 | 22.67 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -88.73 | -65.06 | -75.19 | -75.43 |
| Operating Margin | - | -594.75% | -384.23% | -543.63% | -332.78% |
| Earnings before Tax (EBT) 1 | - | -86.88 | -62.13 | -69.96 | -65.62 |
| Net income 1 | -61.23 | -86.88 | -58.38 | -69.87 | -69.17 |
| Net margin | - | -582.34% | -344.81% | -505.17% | -305.17% |
| EPS 2 | -54.65 | -2.590 | -1.290 | -1.338 | -1.187 |
| Free Cash Flow 1 | - | -82.31 | -35 | -54.5 | -39.5 |
| FCF margin | - | -551.71% | -206.72% | -394.04% | -174.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.243 | 3.56 | 3.827 | 4.289 | 4.396 | 4.43 | 4.463 | 4.43 | 2.144 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.97 | -20.96 | -22.34 | -22.45 | -19.52 | -14.34 | -12.86 | -12.56 | -11.12 |
| Operating Margin | -708.36% | -588.9% | -583.85% | -523.43% | -443.96% | -323.79% | -288.09% | -283.65% | -518.68% |
| Earnings before Tax (EBT) 1 | -24.53 | -19.79 | -21.4 | -21.16 | -16.91 | -13.46 | -11.1 | -10.54 | -9.828 |
| Net income 1 | -24.64 | -19.88 | -21.4 | -20.96 | -17.23 | -12.1 | -10.65 | -10.41 | -9.828 |
| Net margin | -759.85% | -558.31% | -559.26% | -488.65% | -391.9% | -273.09% | -238.73% | -234.93% | -458.29% |
| EPS 2 | -1.930 | -0.4900 | -0.5300 | -0.4800 | -0.4325 | -0.3325 | -0.2775 | -0.2725 | -0.3550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/11/23 | 8/10/23 | 11/9/23 | 4/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.3 | -35 | -54.5 | -39.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | 1 | 2 |
| Capex / Sales | - | - | - | 7.23% | 8.82% |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.64
USD
Average target price
8.4
USD
Spread / Average Target
+412.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.03% | 68.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CARM Stock
- Financials Carisma Therapeutics, Inc.
